Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma

Neoplasia (United States)

Volumn 16, Issue 12, 2014, Pages 1028-1035

  Zhou, Xiaoguang ^a   Tolstov, Yanis ^a   Arslan, Aysenur ^a   Roth, Wilfried ^a   Grüllich, Carsten ^a,b   Pahernik, Sascha ^a   Hohenfellner, Markus ^a   Duensing, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DAUNORUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PUMA PROTEIN; TRANSCRIPTION FACTOR CTCF; ZINOSTATIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; DNA; ONCOPROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DEATH; CELL FATE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; DRUG SENSITIVITY; ECTOPIC EXPRESSION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENOTOXICITY ASSAY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RENAL CANCER CELL LINE; UPREGULATION; CELL SURVIVAL; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, RENAL CELL; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICROSCOPY, FLUORESCENCE; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85003354295     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.09.012     Document Type: Article

References (28)

1. Rini, B.I., Powles, T., Biology and treatment of advanced renal cell carcinoma: a global perspective. Semin Oncol 40 (2013), 419–420.
2. Ueda, K., Cardarelli, C., Gottesman, M.M., Pastan, I., Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84 (1987), 3004–3008.
3. Jackson, S.P., Bartek, J., The DNA-damage response in human biology and disease. Nature 461 (2009), 1071–1078.
4. Sperka, T., Wang, J., Rudolph, K.L., DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 13 (2012), 579–590.
5. Nakano, K., Vousden, K.H., PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7 (2001), 683–694.
6. Yu, J., Zhang, L., Hwang, P.M., Kinzler, K.W., Vogelstein, B., PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7 (2001), 673–682.
7. Yu, J., Zhang, L., PUMA, a potent killer with or without p53. Oncogene 27:Suppl. 1 (2008), S71–S83.
8. Chipuk, J.E., Green, D.R., PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 8 (2009), 2692–2696.
9. Zantl, N., Weirich, G., Zall, H., Seiffert, B.M., Fischer, S.F., Kirschnek, S., Hartmann, C., Fritsch, R.M., Gillissen, B., Daniel, P.T., et al. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26 (2007), 7038–7048.
10. Sturm, I., Stephan, C., Gillissen, B., Siebert, R., Janz, M., Radetzki, S., Jung, K., Loening, S., Dörken, B., Daniel, P.T., Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 13 (2006), 619–627.
11. Tomita, Y., Bilim, V., Kawasaki, T., Takahashi, K., Okan, I., Magnusson, K.P., Wiman, K.G., Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer 66 (1996), 322–325.
12. Bilim, V., Yuuki, K., Itoi, T., Muto, A., Kato, T., Nagaoka, A., Motoyama, T., Tomita, Y., Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer 98 (2008), 941–949.
13. Löber, C., Lenz-Stöppler, C., Dobbelstein, M., Adenovirus E1-transformed cells grow despite the continuous presence of transcriptionally active p53. J Gen Virol 83 (2002), 2047–2057.
14. Adachi, S., Ito, H., Tamamori-Adachi, M., Ono, Y., Nozato, T., Abe, S., Ma, Ikeda, Marumo, F., Hiroe, M., Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ Res 88 (2001), 408–414.
15. Gomes, N.P., Espinosa, J.M., Gene-specific repression of the p53 target gene PUMA via intragenic CTCF-Cohesin binding. Genes Dev 24 (2010), 1022–1034.
16. Kallio, J.P., Hirvikoski, P., Helin, H., Luukkaala, T., Tammela, T.L.J., Kellokumpu-Lehtinen, P., Martikainen, P.M., Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol 172 (2004), 2158–2161.
17. Gobé, G., Rubin, M., Williams, G., Sawczuk, I., Buttyan, R., Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest 20 (2002), 324–332.
18. Fritzsche, F.R., Weichert, W., Röske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Scholman, K., Denkert, C., Dietel, M., et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8 (2008), 381–391.
19. Cancer Genome Atlas Research Network, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 (2013), 43–49.
20. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
21. Hamed, H.A., Das, S.K., Sokhi, U.K., Park, M.A., Cruickshanks, N., Archer, K., Ogretmen, B., Grant, S., Sarkar, D., Fisher, P.B., et al. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biol Ther 14 (2013), 1039–1049.
22. Yamada, T., Horinaka, M., Shinnoh, M., Yoshioka, T., Miki, T., Sakai, T., A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol 43 (2013), 1080–1086.
23. Jones, J., Juengel, E., Mickuckyte, A., Hudak, L., Wedel, S., Jonas, D., Blaheta, R.A., The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 13 (2009), 2376–2385.
24. Tavares, T.S., Nanus, D., Yang, X.J., Gudas, L.J., Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 7 (2008), 1607–1618.
25. Bunz, F., Hwang, P.M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K.W., Vogelstein, B., Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 (1999), 263–269.
26. Xu, C., Meikrantz, W., Schlegel, R., Sager, R., The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc Natl Acad Sci U S A 92 (1995), 7829–7833.
27. Kracikova, M., Akiri, G., George, A., Sachidanandam, R., Aaronson, S.A., A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 20 (2013), 576–588.
28. Jemaà, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L., Senovilla, L., Mariño, G., Malik, S.A., Rello-Varona, S., Lissa, D., et al. Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med 4 (2012), 500–514.